Big Pharma Split Corp.
PRM.TO
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 595.82% | -77.43% | -125.62% | -113.81% | -105.99% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.44% | 41.00% | 904.75% | 422.78% | 296.93% |
| Change in Net Operating Assets | -53.54% | -84.83% | -94.70% | -77.57% | -47.59% |
| Cash from Operations | -74.03% | 17.38% | 932.07% | 2,975.95% | 684.19% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Common Stock | 81.60% | -36.27% | -- | -- | -- |
| Issuance of Preferred Stock | 217.01% | 84.10% | -7.48% | -68.48% | -83.28% |
| Repurchase of Preferred Stock | 100.00% | 0.00% | -- | -- | -- |
| Total Dividends Paid | 16.73% | 19.28% | 22.31% | 15.75% | 7.49% |
| Other Financing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Financing | 84.94% | -3.36% | -596.81% | -4,977.05% | -623.18% |
| Foreign Exchange rate Adjustments | 100.00% | 16.67% | -35.71% | -314.29% | -139.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 325.58% | 149.76% | 4.34% | -268.21% | -256.74% |
